Crohn’s disease, a well-known subtype of inflammatory bowel disease, is an inflammatory condition of the gastrointestinal tract with numerous possible extra-intestinal manifestations. Approximately 40% of all patients affected by Crohn’s disease experience at least one extra-intestinal manifestations of the disease, with the skin being the most common site of extra-intestinal involvement. Other common locations of extra-intestinal involvement include the eyes, joints, and hepatobiliary system. Interestingly, an extra-intestinal manifestation may precede the formal diagnosis of Crohn’s disease in about 25% patients.
Although the underlying etiology of Crohn’s disease remains fundamentally unknown, the largely accepted theory involves exposure to “triggers” (i.e., microbial, environmental, immunological) in a genetically susceptible person. The chronic inflammatory component of Crohn disease is likely driven by altered activation of both Th1 and Th17 immune pathways with elevated levels of interleukins 23 and 17. Polymorphisms of the NOD2/CARD15 genes may further affect the innate immune response. Interestingly, patients with an altered TRAF3IP2 gene may be predisposed to developing cutaneous involvement of their Crohn's disease. Other studies have shown altered intestinal flora (shifts in composition or decreased diversity) in patients with Crohn's disease. Precise etiology and pathogenesis are also limited to the cutaneous manifestations of Crohn’s disease, but assistance in understanding and categorizing these skin findings come from the following three well-accepted categories:
Specific lesions: lesions have histopathological findings consistent with Crohn’s disease on biopsy. This may be further subcategorized to the following:
Reactive lesions: inflammatory lesions that do not share the same histopathological findings.
Associated lesions: likely develop due to shared HLA-gene types or secondary to chronic inflammatory response.
A fourth category is suggested by some authors and encompasses the cutaneous manifestations that may be induced by the treatment of Crohn’s disease, particularly with anti-TNF therapy.
The onset of Crohn’s disease may occur at any age from childhood up to the seventh decade of life, with a majority of the cases diagnosed in young adults between 15 to 30 years of age. Interestingly, approximately 25$ to 35% of all cases of Crohn’s disease are diagnosed in patients younger than 18 years of age. Both the incidence and prevalence of Crohn’s disease have been increasing over the past few decades, particularly in well-developed countries. In the United States, approximately 246 people per 100,000 population are affected by Crohn’s disease and statistically, between 20% to 33% of those patients will experience a dermatological manifestation of their Crohn’s disease.
The clinical presentation of Crohn's disease is immensely diverse and may include any or a combination of any of the following: abdominal pain, anorexia, weight loss, diarrhea, hematochezia, melena, malnutrition, fatigue, fevers, and bowel obstruction secondary to stricture formation. The cutaneous manifestations of Crohn's disease may also aid in establishing the diagnosis of Crohn's disease as their presence may antedate the formal inflammatory bowel disease diagnosis. Although Crohn's disease is well known for its ability to affect any part of the GI tract, from the oral mucosa to the anus, most of the disease is non-contiguous and restricted to the ileum and colon.
Each of the respective categories of the cutaneous manifestations of Crohn disease and their manifestations will be discussed below:
Specific lesions: lesions with histopathological findings consistent with Crohn’s disease on biopsy.
a) Cutaneous lesions which occur due to a direct extension of bowel disease to the skin and are typically seen in the perianal and orofacial areas. Clinically, on the exam, the lesions may be ulcers, fistulae, fissures, or even abscesses and on biopsy, non-caseating granulomatous inflammation can be seen. Many do not actually consider these to truly be an "extra-intestinal" manifestation of Crohn's disease.
b) Metastatic Crohn’s disease: Rare manifestation of cutaneous Crohn's disease characterized by skin lesions with findings of Crohn’s disease on biopsy, but at sites distant and noncontiguous with the GI tract (must be separated from the GI tract by normal tissue).
Reactive lesions: Inflammatory lesions that do not share the same histopathological findings, but are believed to share a similar pathogenesis with Crohn's disease, perhaps due to impaired function of neutrophils or altered cellular immunity.
Associated lesions: likely arise due to shared HLA-gene types or secondary to a chronic inflammatory response. Interestingly, the presence and severity of the cutaneous manifestations listed below generally parallel intestinal disease activity.
Treatment-induced: A novel category of cutaneous findings that are most commonly associated with the treatment of Crohn's disease with anti-TNF biologics. The cutaneous manifestations of anti-TNF treatment do not correlate with disease activity status.
The relative absence or presence of the above cutaneous extra-intestinal manifestations may be helpful in monitoring the disease course of Crohn's disease, particularly in patients displaying oral aphthous ulcerations or erythema nodosum, as they may clue to the physician to evaluate for active intestinal disease, even in relatively asymptomatic patients.
Diagnosis of Crohn's disease is generally made via endoscopic evaluation of intestinal mucosa along with biopsy showing granulomatous changes and crypt irregularities. Additional laboratory evaluation, including blood tests, may also be utilized.
Treatment for the plethora of cutaneous manifestations of Crohn's disease are extensively varied. Each of manifestations that were discussed above will be briefly discussed below.
Specific lesions: lesions with histopathological findings consistent with Crohn’s disease on biopsy
Reactive lesions: inflammatory lesions that do not share the same histopathological findings, but are believed to share a similar pathogenesis with Crohn's disease.
Associated lesions: likely arise due to shared HLA-gene types or secondary to a chronic inflammatory response.
Treatment-induced: A novel category of cutaneous findings that are most commonly associated with the treatment of Crohn's disease with anti-TNF biologics.
|||Yzet C,Brazier F,Fumery M, Post-operative entero-cutaneous fistula closure by Over-The-Scope clip in Crohn's disease. Journal of Crohn's [PubMed PMID: 30596973]|
|||Vide J,Osório F,Costa-Silva M,Lopes S,Azevedo F,Camila Dias C,Magina S,Magro F, Cutaneous Morbidity Among Inflammatory Bowel Disease Patients: A Cohort Study. Journal of Crohn's [PubMed PMID: 29300856]|
|||Vavricka SR,Galván JA,Dawson H,Soltermann A,Biedermann L,Scharl M,Schoepfer AM,Rogler G,Prinz Vavricka MB,Terracciano L,Navarini A,Zlobec I,Lugli A,Greuter T, Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's [PubMed PMID: 29182760]|
|||Alexakis C,Gordon K,Mellor R,Chong H,Mortimer P,Pollok R, Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema. Journal of Crohn's [PubMed PMID: 27683802]|
|||Afzali A,Wheat CL,Hu JK,Olerud JE,Lee SD, The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. Journal of Crohn's [PubMed PMID: 24268978]|
|||Cordova J,Chugh A,Rivera Rivera ED,Young S, Recurrent Pediatric Perianal Swelling. Pediatric annals. 2016 Feb; [PubMed PMID: 26878185]|
|||Romero Gutiérrez M,Alcántara Torres M,Muñoz Rosas C,Gómez Moreno AZ,Guardiola Arévalo A,Rodríguez Merlo R,Carrobles Jiménez JM, [Metastatic Crohn's disease]. Gastroenterologia y hepatologia. 2010 Jun-Jul; [PubMed PMID: 20537428]|
|||Buhr HJ,Kroesen AJ,Stange EF, [Surgery -- fistulas]. Zeitschrift fur Gastroenterologie. 2003 Jan; [PubMed PMID: 12541173]|
|||Huang W,Tang Y,Nong L,Sun Y, Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn's disease: A meta-analysis of observational studies. Journal of Crohn's [PubMed PMID: 25572276]|
|||Barret M,de Parades V,Battistella M,Sokol H,Lemarchand N,Marteau P, Crohn's disease of the vulva. Journal of Crohn's [PubMed PMID: 24252167]|
|||Iborra M,Beltrán B,Bastida G,Aguas M,Nos P, Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. Journal of Crohn's [PubMed PMID: 21453886]|
|||Mocci G,Marzo M,Papa A,Armuzzi A,Guidi L, Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. Journal of Crohn's [PubMed PMID: 23453887]|
|||Torres J,Ellul P,Langhorst J,Mikocka-Walus A,Barreiro-de Acosta M,Basnayake C,Sheng Ding NJ,Gilardi D,Katsanos K,Moser G,Opheim R,Palmela C,Pellino G,Van der Marel S,Vavricka SR, European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. Journal of Crohn's [PubMed PMID: 30820529]|
|||Banasiewicz T,Eder P,Rydzewska G,Reguła J,Dobrowolska A,Durlik M,Wallner G, Statement of the expert group on the current practice and prospects for the treatment of complex perirectal fistulas in the course of Crohn's disease. Polski przeglad chirurgiczny. 2019 Feb 25; [PubMed PMID: 30919811]|
|||Choukour M,Kivits J,Baker A,Baumann C,Guillemin F,Peyrin-Biroulet L, Personalised medicine in inflammatory bowel diseases: a patient survey. Scandinavian journal of gastroenterology. 2019 Jan; [PubMed PMID: 30663451]|
|||Hossne RS,Sassaki LY,Baima JP,Meira Júnior JD,Campos LM, ANALYSIS OF RISK FACTORS AND POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH CROHN'S DISEASE. Arquivos de gastroenterologia. 2018 Jul-Sep; [PubMed PMID: 30540087]|